Literature DB >> 20232107

Methicillin-resistant Staphylococcus aureus (MRSA) in Europe: which infection control measures are taken?

S Hansen1, F Schwab, A Asensio, H Carsauw, P Heczko, I Klavs, O Lyytikäinen, M Palomar, I Riesenfeld-Orn, A Savey, E Szilagyi, R Valinteliene, J Fabry, P Gastmeier.   

Abstract

BACKGROUND: The prevalence of hospital-acquired Methicillin-resistant Staphylococcus aureus (MRSA) infections shows a huge variety across Europe. Some countries reported a reduction in MRSA frequency, while in others countries increasing MRSA rates have been observed. To reduce the spread of MRSA in the healthcare setting, a sufficient MRSA management is essential. In order to reflect the MRSA management across Europe, MRSA prevention policies were surveyed in ten countries.
MATERIALS AND METHODS: The survey was performed by questionnaires in European intensive care units (ICUs) and surgical departments (SDs) in 2004. Questionnaires asked for availability of bedside alcohol hand-disinfection, isolation precautions, decolonization and screening methods. The study was embedded in the Hospital in Europe Link for Infection Control through Surveillance (HELICS) Project, a European collaboration of national surveillance networks. HELICS was initiated in order to harmonize the national surveillance activities in the individual countries. Therefore, HELICS participants developed surveillance modules for nosocomial infections in ICUs and for surgical site infections (SSI). The coordination of this surveillance has now been transferred to the European Centre for Disease Prevention and Control (ECDC).
RESULTS: A total of 526 ICUs and 223 SDs from ten countries sent data on organisational characteristics and policies, demonstrating wide variations in care. Substantial variation existed in availability of bedside alcohol hand-disinfection, which was much higher in participating ICUs rather than in SDs (86 vs. 59%). Surveillance cultures of contact patients were obtained in approximately three-fourths of all SDs (72%) and ICUs (75%). Countries with decreasing MRSA proportions showed especially strict implementation of various prevention measures.
CONCLUSION: The data obtained regarding MRSA prevention measures should stimulate infection control professionals to pursue further initiatives. Particularly, the vigorous MRSA management in countries with decreasing MRSA proportions should encourage hospitals to implement preventive measures in order to reduce the spread of MRSA.

Entities:  

Mesh:

Year:  2010        PMID: 20232107     DOI: 10.1007/s15010-010-0001-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

Review 1.  SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus.

Authors:  Carlene A Muto; John A Jernigan; Belinda E Ostrowsky; Hervé M Richet; William R Jarvis; John M Boyce; Barry M Farr
Journal:  Infect Control Hosp Epidemiol       Date:  2003-05       Impact factor: 3.254

2.  Hospitals in Europe Link for Infection Control through Surveillance (HELICS). Inter-country comparison of rates of surgical site infection--opportunities and limitations.

Authors:  J Wilson; I Ramboer; C Suetens
Journal:  J Hosp Infect       Date:  2007-06       Impact factor: 3.926

3.  Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals.

Authors:  F M MacKenzie; J Bruce; M J Struelens; H Goossens; J Mollison; I M Gould
Journal:  Clin Microbiol Infect       Date:  2007-03       Impact factor: 8.067

4.  Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience.

Authors: 
Journal:  Euro Surveill       Date:  2008-11-13

5.  Infection control practices in intensive care units of 14 European countries. The EURO.NIS Study Group.

Authors:  M L Moro; O B Jepsen
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

6.  National influences on catheter-associated bloodstream infection rates: practices among national surveillance networks participating in the European HELICS project.

Authors:  S Hansen; F Schwab; M Behnke; H Carsauw; P Heczko; I Klavs; O Lyytikäinen; M Palomar; I Riesenfeld Orn; A Savey; E Szilagyi; R Valinteliene; J Fabry; P Gastmeier
Journal:  J Hosp Infect       Date:  2008-09-16       Impact factor: 3.926

7.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.

Authors:  John J Engemann; Yehuda Carmeli; Sara E Cosgrove; Vance G Fowler; Melissa Z Bronstein; Sharon L Trivette; Jane P Briggs; Daniel J Sexton; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2003-02-07       Impact factor: 9.079

Review 8.  Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities.

Authors:  J E Coia; G J Duckworth; D I Edwards; M Farrington; C Fry; H Humphreys; C Mallaghan; D R Tucker
Journal:  J Hosp Infect       Date:  2006-04-03       Impact factor: 3.926

9.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-12-13       Impact factor: 9.079

10.  Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002.

Authors:  Edine W Tiemersma; Stef L A M Bronzwaer; Outi Lyytikäinen; John E Degener; Paul Schrijnemakers; Nienke Bruinsma; Jos Monen; Wolfgang Witte; Hajo Grundman
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

View more
  8 in total

1.  Infection control measures to prevent the transmission of nosocomial pathogens: can or should there be an international consensus?

Authors:  C Ruef
Journal:  Infection       Date:  2010-06       Impact factor: 3.553

Review 2.  Gloves, gowns and masks for reducing the transmission of meticillin-resistant Staphylococcus aureus (MRSA) in the hospital setting.

Authors:  Jesús López-Alcalde; Marta Mateos-Mazón; Marcela Guevara; Lucieni O Conterno; Ivan Solà; Sheila Cabir Nunes; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2015-07-16

3.  Wide variation in adoption of screening and infection control interventions for multidrug-resistant organisms: a national study.

Authors:  Monika Pogorzelska; Patricia W Stone; Elaine L Larson
Journal:  Am J Infect Control       Date:  2012-10       Impact factor: 2.918

4.  Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores.

Authors:  S Y Park; J S Son; I H Oh; J M Choi; M S Lee
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

5.  Screening and control of methicillin-resistant Staphylococcus aureus in 186 intensive care units: different situations and individual solutions.

Authors:  Anke Kohlenberg; Frank Schwab; Michael Behnke; Christine Geffers; Petra Gastmeier
Journal:  Crit Care       Date:  2011-11-25       Impact factor: 9.097

Review 6.  Reducing the risk of infection after total joint arthroplasty: preoperative optimization.

Authors:  Brielle Antonelli; Antonia F Chen
Journal:  Arthroplasty       Date:  2019-08-01

7.  Estimating the effect of practicing nursing professionals density on cumulative carbapenem-resistance prevalence in gram-negative invasive Isolates: a 30 European country observational modeling study.

Authors:  Hani E J Kaba; Simone Scheithauer
Journal:  Antimicrob Resist Infect Control       Date:  2022-02-22       Impact factor: 4.887

8.  Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.

Authors:  Rayo Morfin-Otero; Eduardo Rodriguez Noriega; Michael J Dowzicky
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-12-15       Impact factor: 3.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.